Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients - Summary - MDSpire

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

  • By

  • Guihong Wan

  • Nga Nguyen

  • Charles Lu

  • Sara Khattab

  • Boshen Yan

  • Munachimso Amadife

  • Bonnie W. Leung

  • Wenxin Chen

  • Ahmad Rajeh

  • Kimberly Tang

  • Christopher Thang

  • Genevieve Boland

  • Kerry L. Reynolds

  • Kun-Hsing Yu

  • Alexander Gusev

  • Nicole R. LeBoeuf

  • Shawn G. Kwatra

  • Yevgeniy R. Semenov

  • May 22, 2026

  • 0 min

Share

Objective:

To examine the associations of systemic glucocorticoid immunosuppression (gsISP) timing, dose, and duration with overall survival (OS) in patients treated with immune checkpoint inhibitors (ICIs).

Key Findings:
  • 012
Interpretation:

The impact of gsISP on ICI response remains unclear, particularly regarding timing, dose, and duration.

Limitations:
  • 01
Conclusion:

Further research is needed to clarify the role of gsISP in ICI treatment outcomes across various cancers.

Original Source(s)

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

  • by Guihong Wan, Nga Nguyen, Charles Lu, Sara Khattab, Boshen Yan, Munachimso Amadife, Bonnie W. Leung, Wenxin Chen, Ahmad Rajeh, Kimberly Tang, Christopher Thang, Genevieve Boland, Kerry L. Reynolds, Kun-Hsing Yu, Alexander Gusev, Nicole R. LeBoeuf, Shawn G. Kwatra, Yevgeniy R. Semenov

  • May 22, 2026

Related Content

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases